MicrobiologybioRxivPreprint
FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant
J. Yu, W. Dong, J. Wang…·M. Caligiuri
This study shows FXa cleaves SARS-CoV-2 spike protein, blocking viral entry, but B.1.1.7 variant is resistant, and FXa inhibitors like rivaroxaban reduce this protection.